Floatz logo

Durvalumab

Cervical Cancer

Second Affiliated Hospital of Guangzhou Medical Universitymonoclonal_antibodyPhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
65/ 100

Competitive context

159 Active assets in the Cervical Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 3B
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3B

View all 50 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →